Volume 6, Issue 2 (Vol.6 No.2 Apr 2018)                   rbmb.net 2018, 6(2): 144-150 | Back to browse issues page

XML Print

Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran-Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Abstract:   (2131 Views)

Background: Vascular endothelial growth factor-A (VEGF-A), an endothelial cell-specific mitogen produced by various cell types, plays important roles in cell differentiation and proliferation. In this study we investigated the effect of recombinant VEGF-A on differentiation of mesenchymal stem cells (MSCs) to endothelial cells (ECs).
Methods: VEGF-A was expressed in E. coli BL21 (DE3) and BL21 pLysS competent cells with the pET32a expression vector. Recombinant VEGF-A protein expression was verified by SDS-PAGE and western blotting. Mesenchymal stem cell differentiation to ECs in the presence of VEGF-A was evaluated by flow cytometry and fluorescence microscopy.
Results: Recombinant VEGF-A was produced in E. coli BL21 (DE3) cells at 0.8 mg/mL concentration. Expression of CD31 and CD 144 was significantly greater, while expression of CD90, CD73, and CD44 was significantly less, in MSCs treated with our recombinant VEGF-A than in those treated with the commercial protein (p < 0.05).
Conclusions: Recombinant VEGF-A expressed in a prokaryotic system can induce MSCs differentiation to ECs and can be used in research and likely therapeutic applications.

Full-Text [PDF 471 kb]   (757 Downloads)    
Type of Article: Original Article | Subject: Cell Biology
Received: 2017/04/3 | Accepted: 2017/04/21 | Published: 2017/10/1